| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers C > Headlines for Chemokine Therapeutics Corp. > News item |
Dana-Farber Cancer Institute to investigate Chemokine's CTCE-9908 in brain cancer
By Lisa Kerner
Erie, Pa., Feb. 16 - Chemokine Therapeutics Corp. said it has executed a material transfer agreement to supply the Dana-Farber Cancer Institute in Boston with its lead anticancer compound, CTCE-9908, a chemokine CXCR4 antagonist.
Cancer researchers have demonstrated a correlation between a high level of CXCR4 expression in cancer cells and tumor progression, high metastasis rate and low patient survival rate, according to a company news release. Previous studies have shown CTCE-9908 to reduce cancer metastases by 50% to 70%.
A series of preclinical studies will investigate the drug's ability to inhibit the growth of human brain cancer (glioblastoma) cells.
The Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and a leading cancer research and care center in the United States.
According to the American Cancer Society, about 18,500 malignant tumors of the brain or spinal cord will be diagnosed in the United States this year. About 77% of all malignant brain tumors are gliomas.
Chemokine has completed a phase 1, dose-escalation clinical trial using CTCE-9908 in healthy volunteers that demonstrated CTCE-9908 to be safe and well tolerated, according to a release.
A phase 1b/2 clinical trial, designed to demonstrate safety and explore early signs of efficacy after repeat administration of CTCE-9908, is planned for the first quarter of this year.
Chemokine is a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, cardiovascular and infectious diseases. The company is based in Vancouver, B.C.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.